Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7825175 | 0.91 | MAPK14 (0.48) | MAPK14CYP3A4CYP2C9 | |
| SCHEMBL4831657 | 0.89 | MAPK14 (0.63) | MAPK14CYP3A4CYP2C9SMORAF1 | |
| SCHEMBL4829487 | 0.83 | RAF1 (0.60) | MAPK14RAF1BRAF | |
| SCHEMBL4829475 | 0.82 | MAPK14 (0.48) | MAPK14RAF1BRAF | |
| SCHEMBL4831934 | 0.80 | CSF1R (0.66) | MAPK14RAF1BRAF | |
| SCHEMBL7825479 | 0.80 | MAPK14 (0.51) | MAPK14CYP3A4CYP2C9 | |
| SCHEMBL4824273 | 0.79 | BRAF (0.65) | MAPK14RAF1BRAF | |
| SCHEMBL4831597 | 0.78 | RAC1 (0.61) | MAPK14RAF1BRAF | |
| SCHEMBL4409060 | 0.74 | MAPK14 (0.54) | MAPK14RAF1BRAF | |
| SCHEMBL5897317 | 0.74 | MAPK14 (0.66) | MAPK14CYP3A4CYP2C9SMORAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAPK14 2834/4885CYP3A4 89/4885CYP2C9 85/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAPK14 2834/4885CYP3A4 89/4885CYP2C9 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.